David Shaw’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-767,066
| Closed | -$1.75M | – | 4987 |
|
|
2024
Q2 | $1.75M | Sell |
767,066
-18,193
| -2% | -$69.5K | ﹤0.01% | 2772 |
|
|
2024
Q1 | $3.39M | Buy |
785,259
+289,808
| +58% | +$1.01M | ﹤0.01% | 2200 |
|
|
2023
Q4 | $1.51M | Sell |
495,451
-9,631
| -2% | -$18.1K | ﹤0.01% | 2868 |
|
|
2023
Q3 | $727K | Sell |
505,082
-111,421
| -18% | -$216K | ﹤0.01% | 3253 |
|
|
2023
Q2 | $1.54M | Buy |
616,503
+186,864
| +43% | +$510K | ﹤0.01% | 2822 |
|
|
2023
Q1 | $1.15M | Sell |
429,639
-15,068
| -3% | -$72.4K | ﹤0.01% | 3068 |
|
|
2022
Q4 | $2.41M | Buy |
444,707
+349,733
| +368% | +$2.93M | ﹤0.01% | 2787 |
|
|
2022
Q3 | $1.19M | Sell |
94,974
-42,005
| -31% | -$480K | ﹤0.01% | 3468 |
|
|
2022
Q2 | $677K | Buy |
+136,979
| New | +$759K | ﹤0.01% | 3892 |
|
|
2021
Q1 | – | Sell |
-17,465
| Closed | -$314K | – | 4569 |
|
|
2020
Q4 | $314K | Buy |
+17,465
| New | +$261K | ﹤0.01% | 3590 |
|
|
2020
Q2 | – | Sell |
-51,283
| Closed | -$565K | – | 4303 |
|
|
2020
Q1 | $565K | Buy |
+51,283
| New | +$958K | ﹤0.01% | 3145 |
|
David Shaw's GTHX Position: Q3 2024 in Review
David Shaw sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 767,066 shares — an estimated $1.75M sold.
David Shaw first reported a position in GTHX in Q1 2020 and held it in 11 quarters. The position peaked at $3.39M in Q1 2024. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- David Shaw reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- David Shaw sold 767,066 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $1.75M.
- David Shaw first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
- David Shaw's G1 Therapeutics, Inc. Common Stock position peaked at $3.39M in Q1 2024.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.